• Wondering whether Thermo Fisher Scientific at around US$469.71 is priced attractively or already demanding a premium? This article walks through the key signals that can help you frame that question more clearly.
• The stock has had a mixed run, with a 7 day return of a 10.8% decline, a year to date return of a 20.7% decline, yet a 1 year return of 11.1%. This can leave you questioning whether recent moves reflect changing risk perception or a reset in expectations.
• Recent attention on the stock has focused on its role as a major life sciences and diagnostics provider, with investors watching how market sentiment around healthcare tools and services feeds into Thermo Fisher Scientific's trading range. This helps explain why short term returns look different to the longer term picture, even though the underlying business focus is unchanged.
• On Simply Wall St's valuation checks, Thermo Fisher Scientific currently holds a valuation score of 6 out of 6. The next sections will unpack what this means across different valuation approaches, before ending with a way to think about value that goes beyond the usual ratios.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the business could be worth right now.

For Thermo Fisher Scientific, the latest twelve month Free Cash Flow is about $6.79b. Using a 2 Stage Free Cash Flow to Equity model, analysts and extrapolations point to projected Free Cash Flow of $7.25b in 2026 and $11.95b by 2030, with years after the analyst window estimated by Simply Wall St.

When these projected cash flows are discounted back to today and added up, the model arrives at an estimated intrinsic value of about $606.38 per share. Compared with the current share price of around $469.71, this implies the stock is trading at roughly a 22.5% discount to that DCF estimate, which in this model indicates the shares are undervalued on this cash flow view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 22.5%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it links what you pay per share to the earnings that each share generates. It gives you a quick sense of how much investors are currently willing to pay for each dollar of earnings.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risks. Higher growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually point to a lower P/E.

Thermo Fisher Scientific currently trades on a P/E of about 25.49x. This sits below both the Life Sciences industry average P/E of about 34.17x and a peer group average of 31.70x. Simply Wall St’s Fair Ratio for Thermo Fisher Scientific is 27.49x, which is its proprietary estimate of a suitable P/E given factors like the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for company specific factors instead of assuming all businesses deserve similar P/E levels. Comparing the Fair Ratio of 27.49x with the actual P/E of 25.49x indicates that the shares are trading below that tailored benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to think about valuation. This is where Narratives come in, giving you a simple way to link your view of Thermo Fisher Scientific’s story to a financial forecast and a fair value, then compare that to the current price to decide whether the stock looks attractive or expensive for you.

On Simply Wall St’s Community page, Narratives let investors spell out their assumptions for future revenue, earnings and margins so the numbers clearly reflect the story they believe in. The platform, used by millions of investors, then translates that story into a Fair Value that updates automatically as new news or earnings arrive.

For Thermo Fisher Scientific, one investor might build a more optimistic Narrative that looks similar to the higher analyst cohort, using a Fair Value around US$738.42 with faster assumed revenue growth and higher margins. Another might lean closer to the more cautious end with a Fair Value nearer US$575.00. By comparing each Fair Value with the current share price, those investors can decide whether the gap between price and their own Narrative feels wide enough to act on or better to wait.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.